Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SMP-190
- Development stage
- Unknown
- Lead developer
- Xilinglab
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SMP-190 is an antibody-drug conjugate (ADC) under development for the treatment of solid tumors and unspecified cancers. The drug consists of a monoclonal antibody targeting carcinoembryonic antigen (CEA), conjugated to a topoisomerase I inhibitor payload (Dxd), which is an exatecan derivative. The ADC is designed using the Innovative Coupled Drug Platform to deliver cytotoxic agents directly to CEA-expressing tumor cells, thereby increasing antitumor efficacy while minimizing systemic toxicity. It is being developed by Chengdu Xilingyuan Pharmaceutical Co., Ltd. (also known as Xiling Lab) and is currently in Phase I clinical trials for solid tumors[1][2][3].
02
Targets
TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on SMP-190.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SMP-190.